

01 October 2013

Revised AGM details

Circadian Technologies Limited announces that its Annual General Meeting will now be held as follows:

Date: Friday 29 November 2013.
Time: 11.00 am.
Place: Computershare Conference Centre
Yarra Falls
452 Johnston Street
Abbotsford, Victoria.

Company enquiries
Mark Pryn
Company Secretary - Circadian
Tel: +61 (0) 3 9826 0399 or
rmark.pryn@circadian.com.au

About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer, as well as developing VGX-300 (soluble VEGFR-3) for 'back of the eye' disease such as wet Age Related Macular Degeneration. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.